Bria-MEL+

Bria-MEL+ is an investigational, next-generation, off-the-shelf, cell-based personalized immunotherapy being developed by BriaCell Therapeutics for the treatment of melanoma. It is part of BriaCell’s proprietary platform of targeted cellular immunotherapies designed to activate the patient’s immune system to specifically attack cancer cells while sparing normal tissues. The therapy builds on the company’s experience with similar products in breast and lung cancer (Bria-BRES+, Bria-LUNG+) and aims to provide a novel approach for patients with advanced melanoma. The mechanism involves stimulating anti-tumor immune responses through allogeneic cell-based technology[3][4].